ArticleEuropean journal of pediatrics2025
Lipidomic signatures of tracheal aspirate diagnostic biomarkers in preterm infants with bronchopulmonary dysplasia.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expression and significance of miR-9-5p and GCH1 in neonates with bronchopulmonary dysplasia.Translational pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bronchopulmonary dysplasia (BPD) is a significant pulmonary disorder that often leads to prolonged respiratory complications in preterm infants. This study aimed to characterize the lipidomic profiles in the tracheal aspirate (TA) of extremely preterm infants to identify specific lipid signatures associated with the development of BPD. This study involved 7 infants with BPD and 10 extremely preterm infants without BPD. TA samples were obtained at intubation from the non-BPD infants and at intubation as well as 7 days post-intubation from the BPD infants. Untargeted lipidomic analysis was performed to characterize the lipidomic signatures of TA. A total of 1189 lipid compounds were identified in the TA of infants with BPD and without BPD, with 298 significantly different lipid metabolites between the two groups at intubation. Notably, phosphatidylcholine and phosphatidylethanolamine were significantly decreased, while triglycerides, ceramides, phosphorylated fatty acid analogs, and diglycerides were significantly increased in the infants with BPD. Pathway analysis revealed enrichment of differential lipids in pathways related to insulin resistance, vitamin digestion and absorption, lipolysis regulation in adipocytes, glycerolipid metabolism, fat digestion and absorption, and cholesterol metabolism. After intubation, infants with BPD exhibited 26 up-regulated and 19 down-regulated lipid metabolites, with enrichment primarily in metabolic pathways, including glycerophospholipid metabolism and autophagy.
conclusionThis study identified distinct lipidomic alterations in the TA of BPD infants, suggesting the potential of these lipid profiles as early diagnostic biomarkers and as therapeutic intervention targets. WHAT IS KNOWN: • BPD is a serious pulmonary complication in preterm infants. Lipid synthesis and metabolism are vital for normal lung development. WHAT IS NEW: • Distinct lipidomic profiles in tracheal aspirate differentiate infants with and without BPD. • Tracheal aspirate lipid profiles show strong potential as novel early diagnostic biomarkers and therapeutic targets for BPD.
Indexed as
Identifiers
41186757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.